Stock Ratings / Health Care / HIND / dividends

BOLT (28) KTTA (44) LPCN (37) BIVI (33) ⌘ Pro Terminal →

Vyome Holdings Inc. (HIND) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.75 +1.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Vyome Holdings Inc. (HIND) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $12.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HIND)Realized 20D OHLCV Swing Band: ±11.7%

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HIND)

✓Walkthrough of HIND's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HIND // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -13.79%▼ DESCENDING CHANNEL

2026-10-30O $1.73H $2.14L $1.72C $1.75VOL 42.2K

RES: $2.23SUP: $1.61SMA50: $2.00SMA200: $2.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HIND Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HIND Butterfly Map → + Track HIND →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HIND today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HIND. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HIND today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HIND)

Health Care Rank #828 of 1016 ⚔️ BOLT vs HIND Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HIND vs. BOLT, KTTA, LPCN, BIVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Vyome Holdings Inc. (HIND) ranks #828 by composite RQD confidence (35/100, grade D-) and #876 by equity capitalization ($12.3M). Within this direct 5-issuer industry benchmark cohort, HIND leads on earnings valuation at N/A trailing P/E, while HIND leads on capital efficiency and profitability with -35.0% ROIC and 68.4% gross margin. KTTA currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with HIND at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HIND ACTIVE Vyome Holdings Inc.	D-	35/100	—	68.4%	-35.0%	+1.74%	$12.3M	Benchmark Subject
BOLT Bolt Biotherapeutics Inc.	E	28/100	—	—	-35.0%	-3.34%	$12.3M	/bolt-vs-hind →
KTTA Pasithea Therapeutics Corp.	D	44/100	—	—	-35.0%	-5.95%	$12.3M	/ktta-vs-hind →
LPCN Lipocine Inc.	D-	37/100	—	—	-35.0%	+0.66%	$12.5M	/lpcn-vs-hind →
BIVI BioVie Inc. (Class A)	E	33/100	—	—	-35.0%	-5.48%	$12.0M	/bivi-vs-hind →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001427570

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vyome Holdings Inc. (HIND) reported GAAP revenue of $319.7K (-96.0% vs. FY2024 revenue of $8.0M , and -96.3% cumulative change since FY2023) , GAAP net income of -$10.3M, operating cash flow of -$3.7M, and free cash flow of -$3.7M (-510.4% YoY). On the balance sheet, HIND closed FY2025 with $6.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$319.7K	-$10.3M	-$3.7M	-$3.7M	$6.5M	—
FY2024 (FY)	2024-12-31	$8.0M	-$1.4M	-$614.1K	-$614.1K	$1.4M	—
FY2023 (FY)	2023-12-31	$8.7M	-$11.4M	-$17.0M	-$17.0M	—	—

3. HIND Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HIND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Vyome Holdings Inc. (NASDAQ: HIND) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.75 (+1.74% 1D, market cap $12.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, HIND ranks #828 in composite RQD confidence.

How does HIND compare to BOLT and KTTA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HIND carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 68.4%, and ROIC of -35.0%. By comparison, BOLT (Bolt Biotherapeutics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M) and KTTA (Pasithea Therapeutics Corp.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, HIND leads on earnings multiple (N/A) while HIND leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HIND?

Per HIND's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001427570), Vyome Holdings Inc. generated $319.7K in revenue (-96.0% YoY), -$10.3M in net income, and -$3.7M in free cash flow against $6.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HIND trading relative to its 50-day, 200-day, and 52-week technical levels?

HIND last traded at $1.75 (+1.74% on volume of 13,164 shares), positioning the stock -12.50% below its 50-day simple moving average ($2.00) and -21.88% below its 200-day simple moving average ($2.24). Across its 52-week range of $1.62 to $6.56, HIND sits at the 2.6% percentile with a 14-day RSI of 40.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($1.55 to $1.95).

HIND Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does HIND pay a dividend and is it safe?

Vyome Holdings Inc. (HIND) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: HIND RQD Cockpit HIND 12M Forecast HIND Earnings & Move HIND Dividends & DRIP HIND Insiders & 13F HIND Whale Options HIND Profit Sankey HIND News & Why